Paolino Donatella, Muzzalupo Rita, Ricciardi Antonio, Celia Christian, Picci Nevio, Fresta Massimo
Department of Pharmacobiological Sciences, Faculty of Pharmacy, University Magna Graecia of Catanzaro, Campus Universitario, Building of Biosciences, Viale Europa, I-88100, Germaneto (CZ), Italy.
Biomed Microdevices. 2007 Aug;9(4):421-33. doi: 10.1007/s10544-007-9046-6.
A novel niosome formulation is proposed for topical drug delivery of ammonium glycyrrhizinate, a natural compound with an efficacious anti-inflammatory activity. Niosomes were made up of a new non ionic surfactant, alpha,omega-hexadecyl-bis-(1-aza-18-crown-6) (Bola-surfactant)-Span 80-cholesterol (2:3:1 molar ratio). Niosome vesicles were prepared with the thin layer evaporation method and were physico-chemically characterized. The tolerability of Bola-surfactant both as free molecules or assembled ion niosome vesicles was evaluated in vitro on cultured of human keratinocyte cells (NCTC2544). Human tolerability was evaluated on volunteers. The ability of Bola-niosomes to promote intracellular delivery was evaluated by confocal laser scanning microscopy (CLSM) studies. Human stratum corneum and epidermis (SCE) membranes were used in vitro to investigate the percutaneous permeation. The anti-inflammatory activity of ammonium glycyrrhizinate was evaluated in vivo on human volunteers with a chemically induced erythema. Experimental data show that Bola-niosomes are characterized by a mean size of approximately 400 nm and are able to provide an encapsulation efficiency of 40% with respect to the drug amount used during preparation. CLSM showed that Bola-niosomes were able to promote the intracellular uptake of the delivered substances. Bola-niosomes were also able to significantly improve (p<0.001) the percutaneous permeation of ammonium glycyrrhizinate with respect to both the aqueous drug solution and a physical mixture between unloaded Bola-niosomes and the aqueous drug solution. Bola-niosomes showed a suitable tolerability both in vitro and in vivo. Ammonium glycyrrhizinate-loaded Bola-niosomes determined a significant (p<0.001) and noticeable improvement of the in vivo anti-inflammatory activity of the drug. An effective example of conjugating innovative colloidal carriers, coming from pharmaceutical nanotechnology, and therapeutically effective natural compounds, coming from traditional medicine, was reported.
本文提出了一种新型的非离子表面活性剂囊泡制剂,用于甘草酸铵的局部给药。甘草酸铵是一种具有有效抗炎活性的天然化合物。非离子表面活性剂囊泡由一种新型非离子表面活性剂α,ω-十六烷基双(1-氮杂-18-冠-6)(bola型表面活性剂)-司盘80-胆固醇(摩尔比为2:3:1)组成。采用薄膜蒸发法制备了非离子表面活性剂囊泡,并对其进行了物理化学表征。在人角质形成细胞(NCTC2544)培养物中体外评估了bola型表面活性剂作为游离分子或组装成离子型非离子表面活性剂囊泡的耐受性。在志愿者身上评估了人体耐受性。通过共聚焦激光扫描显微镜(CLSM)研究评估了bola型非离子表面活性剂囊泡促进细胞内递送的能力。体外使用人角质层和表皮(SCE)膜研究经皮渗透。在患有化学诱导红斑的人类志愿者身上体内评估了甘草酸铵的抗炎活性。实验数据表明,bola型非离子表面活性剂囊泡的平均大小约为400 nm,相对于制备过程中使用的药物量,其包封效率为40%。CLSM显示,bola型非离子表面活性剂囊泡能够促进所递送物质的细胞内摄取。相对于药物水溶液以及未负载的bola型非离子表面活性剂囊泡与药物水溶液的物理混合物,bola型非离子表面活性剂囊泡还能够显著提高(p<0.001)甘草酸铵的经皮渗透率。bola型非离子表面活性剂囊泡在体外和体内均表现出合适的耐受性。负载甘草酸铵的bola型非离子表面活性剂囊泡显著(p<0.001)且明显提高了该药物的体内抗炎活性。报道了一个将来自药物纳米技术的创新胶体载体与来自传统医学的治疗有效天然化合物相结合的有效实例。